| Introduction |
|
vii | |
| Abbreviations used in the text |
|
ix | |
|
Introduction to Pharmacology |
|
|
|
|
|
1 | (2) |
|
|
|
3 | (6) |
|
|
|
9 | (7) |
|
The Autonomic Nervous System |
|
|
|
|
|
|
|
|
16 | (1) |
|
Neurotransmitters and Receptors |
|
|
17 | (1) |
|
|
|
18 | (1) |
|
|
|
19 | |
|
Sympathetic vs. Parasympathetic Systems |
|
|
16 | (5) |
|
|
|
21 | (1) |
|
|
|
22 | (2) |
|
|
|
24 | (3) |
|
Adrenoreceptor-Blocking Agents |
|
|
|
Cholinergic-Blocking Agents |
|
|
27 | (6) |
|
|
|
30 | (1) |
|
Neuromuscular Blocking Agents |
|
|
31 | (1) |
|
Ganglionic Blocking Agents |
|
|
32 | (1) |
|
The Central Nervous System |
|
|
|
Anxiolytic and Hypnotic Agents |
|
|
|
|
|
33 | (1) |
|
|
|
34 | (1) |
|
Benzodiazepine Antagonist |
|
|
35 | (1) |
|
|
|
36 | (1) |
|
|
|
|
|
|
37 | (2) |
|
Monoamine Oxidase Inhibitors |
|
|
39 | (1) |
|
Tricyclic Antidepressants |
|
|
40 | (1) |
|
Selective Serotonin Reuptake Inhibitors |
|
|
41 | (1) |
|
Second Generation Antidepressants |
|
|
42 | (1) |
|
Neuroleptic Drugs and Lithium |
|
|
|
|
|
43 | (2) |
|
Phenothiazine Derivatives |
|
|
45 | (1) |
|
|
|
46 | (1) |
|
|
|
46 | (1) |
|
|
|
47 | (1) |
|
|
|
48 | (1) |
|
|
|
|
|
|
49 | (2) |
|
Drugs Used to Treat Partial and Generalized Tonic-Clonic Seizures |
|
|
51 | (2) |
|
Drugs Used to Treat Absence Seizures |
|
|
53 | (2) |
|
Drugs Used to Treat Movement Disorders |
|
|
|
|
|
55 | (1) |
|
Drugs for Parkinson's Disease |
|
|
56 | (2) |
|
Drugs Used to Treat Huntington's Disease |
|
|
58 | (1) |
|
|
|
|
|
|
59 | (2) |
|
|
|
61 | (1) |
|
Intravenous Anesthetic Drugs |
|
|
62 | (4) |
|
|
|
66 | (3) |
|
Opioid Agonists and Antagonists |
|
|
|
|
|
69 | (3) |
|
|
|
72 | (4) |
|
|
|
76 | (1) |
|
Opioid Agonist-Antagonists |
|
|
76 | (1) |
|
|
|
|
|
|
77 | (1) |
|
|
|
78 | (1) |
|
|
|
78 | (1) |
|
|
|
|
|
|
79 | (1) |
|
|
|
80 | (1) |
|
|
|
81 | (1) |
|
|
|
82 | (1) |
|
The Cardiovascular System |
|
|
|
|
|
|
|
|
83 | (2) |
|
|
|
85 | (3) |
|
Peripheral Sympatholytics |
|
|
88 | (4) |
|
|
|
92 | (1) |
|
|
|
93 | (1) |
|
Angiotensin Converting Enzyme Inhibitors |
|
|
94 | (1) |
|
|
|
94 | (1) |
|
Angiotensin II Receptor Antagonist |
|
|
95 | (1) |
|
|
|
96 | (2) |
|
|
|
98 | (3) |
|
|
|
|
|
|
101 | (1) |
|
|
|
102 | (1) |
|
|
|
103 | (1) |
|
|
|
103 | (4) |
|
Congestive Heart Failure Drugs |
|
|
|
|
|
107 | (1) |
|
|
|
108 | (2) |
|
|
|
110 | (4) |
|
Angiotensin Converting Enzyme Inhibitors |
|
|
114 | (1) |
|
Angiotensin II Receptor Antagonist |
|
|
115 | (1) |
|
|
|
116 | (1) |
|
Phosphodiesterase Inhibitors |
|
|
116 | (1) |
|
|
|
|
|
|
117 | (2) |
|
Class I Drugs (Na+ Channel Blockers) |
|
|
119 | (3) |
|
Class II Drugs (β-Adrenergic Blockers) |
|
|
122 | (2) |
|
Class III Drugs (K+ Channel Blockers) |
|
|
124 | (1) |
|
Class IV Drugs (Calcium Channel Blockers) |
|
|
125 | (1) |
|
|
|
126 | (3) |
|
|
|
|
|
|
129 | (2) |
|
Carbonic Anhydrase Inhibitor |
|
|
131 | (1) |
|
|
|
131 | (1) |
|
|
|
132 | (1) |
|
|
|
133 | (1) |
|
Potassium Sparing Diuretics |
|
|
134 | (1) |
|
|
|
135 | (2) |
|
|
|
|
|
|
137 | (1) |
|
|
|
138 | (2) |
|
|
|
140 | (1) |
|
|
|
141 | (2) |
|
|
|
|
|
|
143 | (3) |
|
HMG-CoA Reductase Inhibitors |
|
|
146 | (1) |
|
|
|
146 | (1) |
|
|
|
147 | (1) |
|
|
|
147 | (2) |
|
|
|
|
|
|
149 | (4) |
|
Cell Wall Synthesis Inhibitors |
|
|
|
|
|
153 | (1) |
|
|
|
154 | (4) |
|
|
|
158 | (4) |
|
Carbapenems and Monobactams |
|
|
162 | (1) |
|
|
|
163 | (1) |
|
|
|
164 | (1) |
|
|
|
164 | (1) |
|
Protein Synthesis Inhibitors |
|
|
|
|
|
165 | (1) |
|
|
|
166 | (2) |
|
|
|
168 | (1) |
|
|
|
169 | (1) |
|
|
|
170 | (2) |
|
|
|
172 | (1) |
|
Nucleic Acid Synthesis & Replication Inhibitors |
|
|
|
|
|
173 | (1) |
|
|
|
174 | (1) |
|
|
|
175 | (2) |
|
|
|
|
|
|
177 | (1) |
|
|
|
178 | (1) |
|
|
|
179 | (2) |
|
|
|
181 | (4) |
|
|
|
|
|
|
185 | (1) |
|
|
|
186 | (1) |
|
|
|
187 | (2) |
|
Miscellaneous Antifungal Drugs |
|
|
189 | (2) |
|
|
|
|
|
|
191 | (1) |
|
|
|
192 | (2) |
|
|
|
194 | (2) |
|
|
|
196 | (2) |
|
|
|
|
|
|
198 | (3) |
|
|
|
201 | (1) |
|
|
|
202 | (1) |
|
Drugs for Trypanosomiasis |
|
|
203 | (2) |
|
|
|
|
|
|
205 | (1) |
|
|
|
206 | (2) |
|
Treatment of Trematodes and Cestodes |
|
|
208 | (1) |
|
|
|
|
|
|
209 | (3) |
|
|
|
212 | (2) |
|
|
|
214 | (3) |
|
|
|
214 | (1) |
|
|
|
215 | (1) |
|
Miscellaneous Alkylating Agents |
|
|
216 | (1) |
|
|
|
217 | (2) |
|
|
|
219 | (1) |
|
|
|
220 | (1) |
|
|
|
|
Hypothalamic/Pituitary Hormones |
|
|
|
|
|
221 | (1) |
|
Hormones that Regulate Growth |
|
|
222 | (2) |
|
Hormones that Regulate Gonadal Function |
|
|
224 | (2) |
|
Hormones that Regulate Corticosteroid Release |
|
|
226 | (1) |
|
Posterior Pituitary Hormones and Analogs |
|
|
227 | (2) |
|
Thyroid and Antithyroid Drugs |
|
|
|
|
|
229 | (4) |
|
Treatment of Hypothyroidism |
|
|
233 | (1) |
|
Treatment of Hyperthyroidism |
|
|
234 | (5) |
|
Adrenocorticosteroids and Antagonists |
|
|
|
|
|
239 | (1) |
|
|
|
240 | (2) |
|
Adrenocorticosteroid Antagonists |
|
|
242 | (1) |
|
Mineralocorticoid Therapy |
|
|
243 | (2) |
|
|
|
|
|
|
245 | (1) |
|
|
|
246 | (2) |
|
Progestins/Antiprogestins |
|
|
248 | (2) |
|
|
|
250 | (3) |
|
|
|
253 | (4) |
|
Agents Influencing Bone Mineral Homeostasis |
|
|
|
|
|
257 | (2) |
|
Treatment of Hypocalcemia |
|
|
259 | (1) |
|
Treatment of Hypercalcemia |
|
|
260 | (5) |
|
|
|
|
|
|
265 | (2) |
|
|
|
267 | (1) |
|
|
|
268 | (1) |
|
|
|
269 | (2) |
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs |
|
|
|
|
|
271 | (1) |
|
|
|
272 | (1) |
|
Propionic Acid Derivatives |
|
|
273 | (1) |
|
|
|
273 | (1) |
|
|
|
274 | (1) |
|
|
|
275 | (3) |
|
|
|
|
|
|
278 | (1) |
|
|
|
279 | (3) |
|
|
|
|
|
|
282 | (1) |
|
|
|
283 | (1) |
|
|
|
283 | (3) |
|
|
|
|
Drugs Affecting the Immune System |
|
|
|
|
|
286 | (1) |
|
|
|
287 | (1) |
|
|
|
288 | (1) |
|
Treatment of Migraine Headaches |
|
|
289 | (3) |
|
Treatment of Gastrointestinal Disorders |
|
|
|
Treatment of Acid-Peptic Disease |
|
|
292 | (2) |
|
Treatment of GI Motility Disorders and Emesis |
|
|
294 | (2) |
|
|
|
296 | (3) |
|
|
|
299 | (3) |
|
|
|
|
|
|
302 | (1) |
|
|
|
303 | (1) |
|
|
|
303 | (1) |
|
|
|
304 | (1) |
|
|
|
305 | (3) |
|
|
|
|
|
|
308 | (2) |
|
|
|
310 | (1) |
|
|
|
311 | (2) |
|
Antidotes for Drug Overdose and Poisoning |
|
|
313 | (2) |
|
Perinatal, Pediatric and Geriatric Pharmacology |
|
|
315 | (3) |
|
|
|
318 | (2) |
|
|
|
320 | (2) |
|
Principles of Drug Development |
|
|
322 | (1) |
|
|
|
|
|
|
323 | (3) |
|
Contraceptive Formulations |
|
|
326 | (2) |
|
Calcium Salt Preparations and Uses |
|
|
328 | (1) |
| Index |
|
329 | |